Literature DB >> 21314184

Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release.

Matthew T Basel1, Tej B Shrestha, Deryl L Troyer, Stefan H Bossmann.   

Abstract

Liposomes have become useful and well-known drug delivery vehicles because of their ability to entrap drugs without chemically modifying them and to deliver them somewhat selectively to tumorous tissue via the enhanced permeation and retention (EPR) effect. Although useful, liposome preparations are still less than ideal because of imperfect specificity, slow release kinetics in the tumor, and leakiness prior to reaching the tumor site. Cancer-associated proteases (CAPs), which are differentially expressed in tumors, have also gained traction recently as a method for tumor targeting and drug delivery. By combining the EPR effect with CAPs sensitivity, a much more specific liposome can be produced. The method described here creates an improved liposome system that can target more specifically, with faster release kinetics and lower general leaking, by deliberately producing a very unstable liposome (loaded with hyperosmotic vehicle) that is subsequently stabilized by a cross-linked polymer shell containing consensus sequences for cancer-associated proteases (protease-triggered, caged liposomes). A cholesterol-anchored, graft copolymer, composed of a short peptide sequence for urokinase plasminogen activator (uPA) and poly(acrylic acid), was synthesized and incorporated into liposomes prepared at high osmolarities. Upon cross-linking of the polymers, the protease-triggered, caged liposomes showed significant resistance to osmotic swelling and leaking of contents. Protease-triggered, caged liposomes also showed significant and substantial differential release of contents in the presence of uPA, while bare liposomes showed no differential effect in the presence of uPA. Thus a protease-sensitive liposome system with fast release kinetics was developed that could be used for more specific targeting to tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314184     DOI: 10.1021/nn103362n

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  30 in total

1.  Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.

Authors:  Lin Zhu; Pooja Kate; Vladimir P Torchilin
Journal:  ACS Nano       Date:  2012-03-14       Impact factor: 15.881

Review 2.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

3.  Liposome-like Nanostructures for Drug Delivery.

Authors:  Weiwei Gao; Che-Ming J Hu; Ronnie H Fang; Liangfang Zhang
Journal:  J Mater Chem B       Date:  2013-12-28       Impact factor: 6.331

4.  Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release.

Authors:  Dandan Luo; Kevin A Carter; Aida Razi; Jumin Geng; Shuai Shao; Daniel Giraldo; Ulas Sunar; Joaquin Ortega; Jonathan F Lovell
Journal:  Biomaterials       Date:  2015-10-23       Impact factor: 12.479

Review 5.  siRNA Delivery by Stimuli-Sensitive Nanocarriers.

Authors:  Giuseppina Salzano; Daniel F Costa; Vladimir P Torchilin
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules.

Authors:  Sheila M Barros; Susan K Whitaker; Pinakin Sukthankar; L Adriana Avila; Sushanth Gudlur; Matt Warner; Eduardo I C Beltrão; John M Tomich
Journal:  Arch Biochem Biophys       Date:  2016-02-27       Impact factor: 4.013

7.  Ultrasound enhanced matrix metalloproteinase-9 triggered release of contents from echogenic liposomes.

Authors:  Rahul Nahire; Shirshendu Paul; Michael D Scott; Raushan K Singh; Wallace W Muhonen; John Shabb; Kara N Gange; D K Srivastava; Kausik Sarkar; Sanku Mallik
Journal:  Mol Pharm       Date:  2012-08-15       Impact factor: 4.939

Review 8.  The smart targeting of nanoparticles.

Authors:  Adam D Friedman; Sarah E Claypool; Rihe Liu
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

Review 10.  Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems.

Authors:  Mahdi Karimi; Amir Ghasemi; Parham Sahandi Zangabad; Reza Rahighi; S Masoud Moosavi Basri; H Mirshekari; M Amiri; Z Shafaei Pishabad; A Aslani; M Bozorgomid; D Ghosh; A Beyzavi; A Vaseghi; A R Aref; L Haghani; S Bahrami; Michael R Hamblin
Journal:  Chem Soc Rev       Date:  2016-03-07       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.